Authors: Xingyuan Hu, Xiaoyan Kang, Faming Zhao, Yaoyuan Cui, Yu Fu, Xiaohang Yang, Jingjing Yin, Wenting Li, Junpeng Fan, Bin Yang, Zixuan Fang, Tianyu Qin, Xucui Zhuang, Yiting Liu, Chenzhao Feng, Yunyi Yang, Funian Lu, Li Zhang, Weihao Chen, Miaofang Wu, Ning Du, Xia Sheng, Xin Zhou, Jing Li, Gang Chen, Chaoyang Sun
Published: 2025-03-12
DOI: 10.1126/scitranslmed.adp2124
Source: Full article
The benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer remains controversial, hindering the development of rational combination therapies based on hyperthermia (HT). This study reports the preliminary results of the neoadjuvant HIPEC (NHIPEC) trial (ChiCTR2000038173), demonstrating enhanced tumor response in high-grade serous ovarian cancer with NHIPEC. Through single-cell RNA sequencing analysis, we identified both homogeneous and heterogeneous cellular responses to HT within the tumor and microenvironment. Epithelial-mesenchymal transition–activated tumor cells and matrix metallopeptidase 11 (MMP-11)